RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some
block the ability of tumor cells to grow and spread. Others find tumor cells and help kill
them or carry tumor-killing substances to them. It is not yet known whether temozolomide is
more effective when given with or without bevacizumab in treating patients with recurrent
glioma.
PURPOSE: This randomized clinical trial is studying how well temozolomide works with or
without bevacizumab in treating patients with recurrent glioma.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC